Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.60 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL388562 | 0.84 | CYP3A4 (0.73) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL5503979 | 0.82 | CYP3A4 (0.67) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL29183811 | 0.82 | CYP3A4 (0.58) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL1537285 | 0.82 | CYP3A4 (0.71) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL163444 | 0.82 | CYP3A4 (0.71) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL3393715 | 0.81 | CYP3A4 (0.65) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL93943 | 0.81 | CYP3A4 (0.65) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL28504890 | 0.81 | CYP3A4 (0.57) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL3435176 | 0.81 | CYP3A4 (0.69) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 | |
| SCHEMBL153062 | 0.81 | CYP3A4 (0.69) | CYP3A4SLC7A5HRH4HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767826-B2 | Process for the synthesis of L-(+)-ergothioneine | PHARMATECH INTERNATIONAL, INC. (US) | 2010-08-03 | — | — | US | claimed |
| US-20090093642-A1 | PROCESS FOR THE SYNTHESIS OF L-(+)-ERGOTHIONEINE | PHARMATECH INTERNATIONAL, INC. | 2009-04-09 | — | — | US | claimed |
| WO-2009045413-A1 | PROCESS FOR THE SYNTHESIS OF L-(+)-ERGOTHIONEINE | PHARMATECH INTERNATIONAL, INC. (US) | 2009-04-09 | — | — | WO | claimed |
| CN-1133173-A | Preparation of diuretic by using neuropsychic tension antagonist | SANOFI SA (FR) | 1996-10-16 | — | — | CN | claimed |
| WO-2023217589-A1 | POLYAMIDE MICROCAPSULES | FIRMENICH SA (CH) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023217590-A1 | POLYAMIDE MICROCAPSULES | FIRMENICH SA (CH) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023155006-A1 | TOTAL SYNTHESES OF SELENONEINE, ISO-SELENONEINE, AND ISOMERS | UNIVERSITé LAVAL (CA) | 2023-08-24 | — | — | WO | disclosed |
| US-20200369727-A1 | COMPOSITION AND METHOD FOR TREATING A PATIENT HAVING LIVER CIRRHOSIS | KING ABDULAZIZ UNIVERSITY (SA) | 2020-11-26 | — | — | US | disclosed |
| US-20200308228-A1 | PEPTIDE INHIBITORS OF HCV NS3/4A PROTEASE COMPRISING NON-PROTEINOGENIC AMINO RESIDUES | KING ABDULAZIZ UNIVERSITY (SA) | 2020-10-01 | — | — | US | disclosed |
| CN-107267517-A | Noval chemical compound for treating, delaying and/or preventing human genetic disease's such as type of steirert-Batten-Gibb syndrome 1 | 比奥马林技术公司 | 2017-10-20 | — | — | CN | disclosed |
| CN-103747805-B | Compounds for the treatment, delay of progression and/or prevention of human genetic disorders such as myotonic dystrophy type 1 (DM 1) | 比奥马林技术公司 | 2017-08-29 | — | — | CN | disclosed |
| US-7767826-B2 | Process for the synthesis of L-(+)-ergothioneine | PHARMATECH INTERNATIONAL, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| CN-1674891-A | Porphyrin oxygen infusion preparation for increasing oxygen concentration in tumor tissue | NIPRO CORP (JP) | 2005-09-28 | — | — | CN | disclosed |
| EP-1572244-A1 | ORAL FORMULATIONS FOR POORLY ABSORPTIVE HYDROPHILIC DRUGS | Chong Kun Dang Pharmaceutical Corp. (KR) | 2005-09-14 | — | — | EP | disclosed |
| EP-1512399-A1 | PORPHYRIN OXYGEN INFUSION PREPARATION FOR INCREASING OXYGEN CONCENTRATION IN TUMOR TISSUE | Nipro Corporation (JP) | 2005-03-09 | — | — | EP | disclosed |
| WO-2004052405-A1 | ORAL FORMULATIONS FOR POORLY ABSORPTIVE HYDROPHILIC DRUGS | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2004-06-24 | — | — | WO | disclosed |
| CN-1133173-A | Preparation of diuretic by using neuropsychic tension antagonist | SANOFI SA (FR) | 1996-10-16 | — | — | CN | disclosed |
| WO-1990006914-A1 | N-ALKYLATION OF N-ALPHA-BOC-PROTECTED AMINO ACIDS | THE UPJOHN COMPANY (US) | 1990-06-28 | — | — | WO | disclosed |
| US-4870183-A | RENIN INHIBITORS, HYPOTENSIVES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1989-09-26 | — | — | US | disclosed |
| EP-0252727-A1 | Novel amino acid derivatives | Kissei Pharmaceutical Co. Ltd. (JP) | 1988-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308228-A1 | PEPTIDE INHIBITORS OF HCV NS3/4A PROTEASE COMPRISING NON-PROTEINOGENIC AMINO RESIDUES | DPP4, CTRL, GTF3C4 | CYP3A4 328/4885SLC7A5 2931/4885HRH4 2934/4885 |
| US-20200369727-A1 | COMPOSITION AND METHOD FOR TREATING A PATIENT HAVING LIVER CIRRHOSIS | RNGTT, RNASE1, FABP1 | CYP3A4 363/4885SLC7A5 3881/4885HRH4 2626/4885 |
| US-20090093642-A1 | PROCESS FOR THE SYNTHESIS OF L-(+)-ERGOTHIONEINE | TTPA, DTYMK, TST | CYP3A4 1118/4885SLC7A5 205/4885HRH4 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.